SELLAS Life Sciences Group (SLS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on SELLAS Life Sciences Group (SLS) is Neutral.

The composite score behind that read is -0.08, weighing +0.16 of bullish evidence against -0.29 bearish.

SELLAS Life Sciences Group last closed at $11.74, +3.62% on the session.

Against the IVW growth benchmark the position is +2.65% over the forecast window.

The read is built from 13 underlying insights — 6 bullish and 7 bearish.

Agreement across those insights is 54%.

SELLAS Life Sciences Group has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks SELLAS Life Sciences Group in the 21st percentile on return on equity, where 100 is best.

SELLAS Life Sciences Group is classified under Health Care / Biotechnology, with a market capitalisation of $2.29B.

StockMap tracks SELLAS Life Sciences Group as the 67th largest of the 250 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 124 Neutral, 117 Moderate Underperform, 8 Strong Underperform and 1 Moderate Outperform.

On that composite SELLAS Life Sciences Group ranks 60th of 250 in the group, against a group median of -0.21.